Buformin

• Description :

  Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) [1].

• Product Name Alternative :

  1-Butylbiguanide

• UNSPSC :

  12352211

• Target :

  AMPK

• Type :

  Reference compound

• Related Pathways :

  Epigenetics; PI3K/Akt/mTOR

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Cancer; Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/buformin.html

• Solubility :

  10 mM in DMSO

• Smiles :

  NC(NC(NCCCC)=N)=N

• Molecular Formula :

  C6H15N5

• Molecular Weight :

  157.22

• References & Citations :

  [1]Amanda B Parris, et al. Buformin Inhibits the Stemness of erbB-2-overexpressing Breast Cancer Cells and Premalignant Mammary Tissues of MMTV-erbB-2 Transgenic Mice. J Exp Clin Cancer Res|[2]Jing Li, et al. Buformin Suppresses Proliferation and Invasion via AMPK/S6 Pathway in Cervical Cancer and Synergizes With Paclitaxel. Cancer Biol Ther. 2018 Jun 3;19 (6) :507-517.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Citation 01 :

  ACS Appl Nano Mater. 2023 Oct 26.|Clin Sci. 2022 Feb 25;136 (4) :273-289.|Mol Metab. 2024 Jan:79:101860.

• CAS Number :

  [692-13-7]